Raymond James reiterates Strong Buy on Viking Therapeutic stock By Investing.com

Raymond James reiterated a Strong Buy on Viking Therapeutics with a $118 price target, saying the tirzepatide vs. semaglutide body-composition data are neutral to positive for VKTX. The firm argued lean body mass loss appears similar when scaled to total weight loss, which reduces a potential competitive concern for Viking’s GLP-1/GIP program. The article also notes completion of enrollment in the Phase 3 VANQUISH-2 trial for VK2735, supporting the stock’s clinical development narrative.

Analysis

The setup is less about the headline medical takeaway and more about positioning around scarcity of differentiated obesity assets. If the lean-mass narrative is neutralized, the market should keep rewarding drugs with the cleanest efficacy/safety and scale profile, which supports VKTX as a credible call option on the next phase of obesity share capture rather than a company-specific story. The bigger second-order effect is on the broader GLP-1 complex: if body-composition concerns fail to create product differentiation, then label expansion, supply reliability, and convenience remain the main battlegrounds, which favors incumbents with manufacturing depth over pure-plays.

For VKTX, the near-term risk is not the pre-print debate itself but execution into Phase 3 readouts over the next 6-18 months. In obesity biotech, multiple compression usually happens when traders realize that “good enough” efficacy is priced in before the first clean pivotal dataset, so any delay, tolerability issue, or weaker-than-expected placebo-adjusted weight loss could rapidly unwind the premium. Conversely, if the program keeps de-risking, the stock can rerate violently because the float is still primarily driven by binary clinical milestones rather than fundamentals.

The most interesting contrarian angle is that the market may be underestimating how little incremental differentiation the lean-mass debate actually provides across incretin drugs. If body composition is not a real wedge, then pricing and adherence become the real battleground, and that reduces the chance that smaller competitors win purely through “better quality loss” messaging. That is mildly supportive for the highest-conviction incumbent franchises, but it also means investor attention can swing back to who can produce the next credible dual-agonist with supply at scale.

INTC is likely just a sentiment spillover in the tape, not a direct fundamental linkage from this item; treat it as noise unless confirmed by company-specific earnings or guidance. MS is effectively unaffected.

Key Decisions for Investors

• Maintain a tactical long VKTX into the next 2-8 weeks, but size it as a binary catalyst trade rather than a fundamental core; upside is a continued de-risking rerate, while downside is sharp if Phase 3 expectations drift lower.
• Use call spreads in VKTX for the next clinical milestone window instead of outright stock if implied volatility is elevated; this preserves upside while capping premium bleed if the catalyst timing slips.
• For a relative-value expression, consider long VKTX / short a basket of crowded obesity winners over 1-3 months if you want exposure to single-name clinical upside without taking full sector beta.
• Avoid overreacting to the lean-mass debate by shorting the incumbent incretin leaders on this print alone; the information content is weak, and the primary winners remain the names with manufacturing scale and adherence advantages.
• Do not initiate an INTC or MS position on this article; any move there should be treated as unrelated tape noise unless a separate fundamental catalyst emerges.